Neurocrine Biosciences | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 9.71B 96M 2025-06
Acadia Pharmaceuticals USD 232.19M 7.16M 2025-06
Agios Pharmaceuticals USD 139.51M 24.16M 2025-06
ALKERMES USD 297.68M 4.96M 2025-06
Alnylam Pharmaceuticals USD 789.89M 213.78M 2025-06
Amgen USD 6.52B 337M 2025-06
Biogen USD 1.79B 326.1M 2025-06
BioMarin Pharmaceutical USD 548.52M 27.27M 2025-06
Cytokinetics USD 178.28M 21.06M 2025-06
Dynavax Technologies USD 81.01M 10.78M 2025-06
Exelixis USD 354.68M 13.9M 2025-07
Gilead Sciences USD 4.35B 80M 2025-06
Halozyme Therapeutics USD 123.28M 48K 2025-06
Incyte USD 904.7M 56.97M 2025-06
Ionis Pharmaceuticals USD 312.21M 34.21M 2025-06
Neurocrine Biosciences USD 541.9M 7M 2025-06
Pfizer USD 11.62B 1.58B 2025-06
Prothena USD 56.43M 10.59M 2025-06
Regeneron Pharmaceuticals USD 2.6B 159.1M 2025-06
Repligen USD 176.41M 13.82M 2025-06
Sarepta Therapeutics USD 495.51M 549.73M 2025-06
Teva Pharmaceutical Industries USD 3.28B 95M 2025-06
Ultragenyx Pharmaceutical USD 274.38M 7.85M 2025-06
Vertex Pharmaceuticals USD 1.81B 71.4M 2025-06


Neurocrine Biosciences Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Sep 2025.